Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial — Robert Bissonnette (2014) | RDL Network
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
Article 2014 en
Authors
RB
Robert Bissonnette
LI
Lars Iversen
HS
Howard Sofen
Abstract
1 min read
Patients who received continuous treatment maintained a response more effectively when compared with placebo recipients. Safety profiles were comparable in both the continuous treatment group and retreatment group. Of those patients who relapsed, up to 60% recaptured a response with tofacitinib.
Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, Scott T. Rottinghaus, Hsiewe Ying Tan, James Proulx, H. Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk
Maria Teresa Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A Dimopoulos, Igor Wolfgang Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell, Joan Bladé
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.